Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02165007 · ClinicalTrials.gov registry record · Phase 1
Haploidentical Hematopoietic Stem Cell Transplantation
A Phase 1 study, sponsored by Catherine Bollard.
- Completed
- Registry status
- Phase 1
- Development phase
- 7
- Enrollment target
NCT02165007: Completed Phase 1 study, sponsored by Catherine Bollard.
NCT02165007 is a Phase 1 study that has completed, run by Catherine Bollard. The registered enrollment target is 7 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (88% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02165007, a Phase 1 study, has completed, sponsored by Catherine Bollard.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 7 participants
- Enrollment target
Study Summary
The study is designed as a Pilot/Phase 1 trial of reduced intensity Haploidentical HSCT in patients with sickle cell disease and thalassemia. The purpose of the study is to assess the safety and toxicity of reduced intensity conditioning haploidentical hematopoietic stem cell transplantation.
Primary Outcome
The primary endpoint of this trial is safety. Transplant related adverse outcomes and non-hematological toxicity will be measured through Day +60 on this objective to include: * Non-hematological severe (Grade IV and V) organ specific toxicity according to the Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0) * Rates of non-engraftment * Severe acute (Grade III-IV) * Veno-occlusive disease of the liver * Idiopathic pneumonia syndrome * Seizures/Posterior reversible encephalopa
Interventions
- DRUG peripheral blood stem cell graft that are CD34+ selected
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2015-01 |
| Est. Completion | 2024-10 |
| Phase | Phase 1 |
What the finished NCT02165007 record still lists
NCT02165007 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 7 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (88% lower).
The record links to 0 conditions, and to 1 intervention - of which peripheral blood stem cell graft that are CD34+ selected is the first listed.
NCT02165007 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02165007 about?
NCT02165007 is a clinical study titled "Haploidentical Hematopoietic Stem Cell Transplantation". The study is designed as a Pilot/Phase 1 trial of reduced intensity Haploidentical HSCT in patients with sickle cell disease and thalassemia. The purpose of the study is to assess the safety and toxicity of reduced intensity conditioning haploidentical hematopoietic stem cell transplantation.
What is the current status of trial NCT02165007?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 7 participants. The study started on 2015-01. Estimated completion is 2024-10.
What interventions are being tested in trial NCT02165007?
The interventions under investigation include: peripheral blood stem cell graft that are CD34+ selected (DRUG).
Who is sponsoring clinical trial NCT02165007?
This trial is sponsored by Catherine Bollard, which has 14 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02165007's enrollment target sits among peer trials
7 1972nd of 2000 higher than 27 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia